Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Cash from Financing Activities (2016 - 2025)

Collegium Pharmaceutical (COLL) has 10 years of Cash from Financing Activities data on record, last reported at -$21.8 million in Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 47.14% year-over-year to -$21.8 million; the TTM value through Dec 2025 reached -$110.2 million, down 81.91%, while the annual FY2025 figure was -$110.2 million, 81.91% down from the prior year.
  • Cash from Financing Activities reached -$21.8 million in Q4 2025 per COLL's latest filing, down from -$14.8 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $517.8 million in Q1 2022 and bottomed at -$114.2 million in Q2 2024.
  • Average Cash from Financing Activities over 5 years is $1.8 million, with a median of -$26.2 million recorded in 2021.
  • Peak YoY movement for Cash from Financing Activities: crashed 242.64% in 2021, then surged 4614.86% in 2022.
  • A 5-year view of Cash from Financing Activities shows it stood at -$42.5 million in 2021, then surged by 39.24% to -$25.8 million in 2022, then plummeted by 162.66% to -$67.8 million in 2023, then soared by 39.14% to -$41.3 million in 2024, then soared by 47.14% to -$21.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were -$21.8 million in Q4 2025, -$14.8 million in Q3 2025, and -$48.4 million in Q2 2025.